Trevena, Inc. (OTCPK: TRVN)
Health Care · Biotechnology · US
$0.00
-90.99% today · -16.7% 1Y
Trevena, Inc. (OTCPK: TRVN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $959.00 and employs 23 people.
Over the last twelve months the share price has lost 16.7%, trading between 0.00 and 1.50.
Tweenvest scores Trevena, Inc. across four factors: quality 11/100, value 39/100. Its strongest factor is value.
TRVN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $959.00
- Revenue (TTM)
- $546.00K
- P/E
- —
- EPS
- -42.72
- Dividend yield
- —
- Beta (5Y)
- -0.41
- 52-week high
- $1.50
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 958.79K
- Employees
- 23
- Next earnings
- —
About Trevena, Inc.
Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid receptor agonist under development for the treatment of acute migraine. TRV734: A small molecule G protein-biased MOR ligand designed for the management of both moderate-to-severe acute and chronic pain. TRV045: An innovative S1P modulator focused on providing relief for chronic pain. The company has also established a partnership with Imperial College London to investigate TRV027's potential in patients afflicted with COVID-19. Trevena, Inc., founded in 2007, operates from its headquarters in Chesterbrook, Pennsylvania.
- ISIN
- US89532E3071
- Founded
- 2007
- Listed since
- Jan 31, 2014
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.